Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass Post published:February 19, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 16, 2024 Post category:Analysis/Pα+
Natural Medicine Advisory Bulletin #8.1: Recommendation Round-up Post published:February 15, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Natural Medicine Advisory Bulletin #8: January 2024 Post published:February 14, 2024 Post category:Colorado Natural Medicine Advisory Bulletin
Pα+: Day 1 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA Post published:February 14, 2024 Post category:Analysis/Pα+
Psychedelic Research Bulletin: January 2024 Post published:February 12, 2024 Post category:Psychedelics Research Review
The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023 Post published:February 9, 2024 Post category:2023 Year in Review/Analysis
Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists Post published:February 8, 2024 Post category:Psychedelic Bulletin/Pα+
The Psychedelic Drug Development Pipeline: Bullseye Chart Year-End 2023 Post published:February 6, 2024 Post category:2023 Year in Review/Analysis
The Psychedelic News Feed: Jan 8 2024 – Feb 4, 2024 Post published:February 5, 2024 Post category:Psychedelic News Feed Archive